汉防己甲素配合放射线增敏治疗鼻咽癌的临床研究

Clinical study of tetrandrine as radiosensitizer treating nasopharyngeal carcinoma

目的：观察汉防己甲素用于鼻咽癌放疗的增敏作用及其毒副反应。方法：112例鼻咽癌患者随机分为治疗组和对照组。治疗组在放疗第1天开始服用汉防己甲素，每次40mg，每天3次，直至放疗结束，放疗采用6MV-X线常规分割外放射治疗，鼻咽部DT66～72Gy／33～36F／6～7w，颈部淋巴结转移灶治疗量DT60～66Gy／30～33F／6～7W。对照组单纯放疗，其设野和剂量均同治疗组。结果：放疗结束后1个月鼻咽部MRI复查评价疗效，近期有效率治疗组为89．3％，对照组为69．6％，治疗组近期疗效明显，差异有显著意义（P〈0．05）；治疗组放疗期间骨髓抑制、放射性皮炎、口干、咽痛和消化道反应等同对照组比较无显著性差异（P〉0．05）。结论：鼻咽癌放疗中汉防己甲素是一种理想的放射增敏剂，值得在临床上进一步应用推广。

Objective To observe the radiosensitizing effect and side-effects of tetrandrine in combination with radiotherapy in treatment of nasopharyngeal carcinoma（NPC）. Methods 112 patients with NPC were randomly divided into the sensitization group and the control group. In the sensitization group, all patients were treated by conventional fractional radiotherapy with a total dose of 66 - 70 Gy/33 - 36 F/6 - 7 W by 6 MV-X-ray. During radiotherapy of the sensitization group, all the patients took tetrandrine 40 mg every time and three times per day. In the Control group, all patients were given to the same as the sensitization group in radiotherapy. Results The short-term overall response rate of the sensitization group（ 89.3% ） was significantly higher than the control group（69.6% ）. There was not a significant difference between the 2 groups （P 〉 0.05 ） on side-effects. Conclusion Tetrandrine is an ideal radiosensitizer during NPC radiotherapy.